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Abstract
Background: Controversy abounds over whether breast cancer in younger women is more
aggressive than those in older. The aim of the study was to assess the influence of age on long-term
survival of women with breast carcinoma.
Materials and Methods: Patients with non-metastatic and non-inflammatory invasive breast
carcinoma treated at the Regional Cancer Centre, Trivandrum, Kerala, India during 1990–93 were
divided into 4 age groups as < 40 years, 40–49, 50–59, and > 60 years. The overall survival (OS)
for each age group was estimated using the Kaplan-Meier method in relation to the primary tumor
(T) and the axillary node status (N). The OS of the various age groups were compared using the
log-rank test. Hazard ratio and 95% confidence interval for each age group was estimated using
Cox-regression model after adjusting for T and N.
Results: Between 1990–1993, 1701 women (26%, <40 years) reported with non-metastatic and
non-inflammatory invasive breast carcinoma. Overall survival (OS) of all the women was 52.6 %
(standard error 1%) at 10 years. The OS for women with age < 40 years and with T3 and T4 disease
status was 36.6% and 10.4% respectively and for those in 40–49 age group was 41.9% and 33.5%.
The 10-year OS for women with node positive (N1) disease was 24.6% in < 40 years and 45.2% in
the 40–49 age group (p = 0.0006). After adjusting for tumor and node stage the relative risk for
death was 24% lower for women in 40–49 age group as compared to women <40 years of age.
Conclusion: Women under 40 years with T3/ T4 breast lesions and/or positive axillary nodes
were found to have a significantly poorer survival.
Introduction
The effect of age on survival in women with breast carci-
noma is controversial. Several studies have reported that
younger age to be associated with poorer prognosis when
compared to older patients [1-6]. Other studies have
reported that younger women have a better chance of sur-
vival [7-9]. There are reports of peri-menopausal women
having a good prognosis [4,10-12]. However, in a few
studies, no significant correlation between age and prog-
nosis has been obtained [13-15]. It remains unclear as to
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whether the different outcome of treatment seen in the
various age groups is a reflection of aggressiveness of the
disease and underlying tumor biology. Thus the effect of
age on prognosis still seems controversial. The aim of the
present study was to assess the influence of age on long-
term (10-year) survival in breast cancer patients treated at
Regional Cancer Centre (RCC), Trivandrum, Kerala,
India. The results were controlled for the extent of disease
at diagnosis (T and N stage), which is a major determinant
of survival.
Materials and methods
Between 1990–1993, 1701 women with non-metastatic
and non-inflammatory invasive breast carcinoma were
treated at RCC, Trivandrum. The follow-up period lasted
until December 2000. Women were grouped according to
age into <40 years, 40–49, 50–59, and > 60 years. Diagno-
sis and treatment particulars were abstracted from the
patient medical records. Tumor size was classified into T1
(< 2 cm.), T2 (2 cm. to less than 5 cm.), T3 (5 cm. or more)
and T4 (any size with direct extension to chest wall or
skin) and Tx, if the details of the primary tumor were not
known (UICC-TNM classification). Lymph node status
was histologically assessed and was classified as node neg-
ative and node positive. All patients had undergone sur-
gery and/or radiotherapy with or without adjuvant
chemotherapy and/or hormone therapy as per the institu-
tional protocol.
Information on patient outcome was obtained through
periodic follow-up of patients at RCC, Trivandrum. The
information on lost to follow-up patients was obtained
through repeated reply-paid postal enquiry. As this was
not cause specific survival estimation, all causes of deaths
were accounted as 'event'. All other patients were 'cen-
sored' as on December 2000. The follow-up time was cal-
culated from the date of diagnosis.
The OS for the various age groups were estimated in rela-
tion to the primary tumor (T) and the nodal status (N)
using the Kaplan-Meier method [16]. The OS of these age
groups were compared using log-rank test. Prognosis
(hazard ratios and 95% confidence interval) of each age
group was estimated using Cox-regression model [17]
after adjusting for T and N.
Results
The data collected were grouped into 4 according to age: <
40 years (n = 437), 40–49 years (n = 557), 50–59 years (n
= 433), and > 60 years (n = 274). The median age was 46
years (range: 21–90 years). The median follow-up was 66
months. At the end of the study period, that is December
2000, 640 (38%) patients were dead while 556 failed. Of
these 556 patients, 125 (22.4%) had metastasis in bone
(7.1% spine), 41 (7.3%) in liver, 40 (7.1%) in lung, 34
(6.1%) in brain, 20 (3.5%) in opposite breast and 169
(30.3%) had multiple metastasis. The rest 127 failed
locally (22.8%). The distribution of patients in each age
group by T and N is summarized in Table 1. Node positiv-
ity was higher among women under 40 years (60%) as
compared to women > 60 years (55%) (Table 1). This dif-
ference, however, was not statistically significant (p =
0.12).
The 10-year OS for the whole group was 52.6% [standard
error (SE) 2%] (Figure 1), it was 46.5% for women with
age <40 years and 59.8% for the 40–49 years age group (p
= 0.0001) (Table 2) (Figure 2). Survival for the above four
age groups was estimated in relation to T (Figures 3, 4, 5,
6) and N (Figures 7 &8) (Tables 3, 4, 5, 6). In women aged
<40 years, and >60 there was a significant drop in survival
in T4-stage. However, this was not seen in women aged
40–49, and 50–59 years and in patients with T1 to T3 dis-
ease. When T-status alone was considered, those under the
age of 40 years and with T1, T2 disease had a 10-year OS
of 62.3% and 58.3% respectively (Table 3). For those pre-
Table 1: Non-metastatic and non-inflammatory breast carcinoma. Distribution of age group by Tumor stage and Nodal status
Tumor status Age (years)
<40 40–49 50–59 60–69 Total
Total 437 557 433 274 1701
T1 51 (11.7)* 64 (11.5) 49 (11.3) 42 (15.3) 206
T2 204 (46.7) 268 (48.1) 222 (51.3) 125 (45.6) 819
T3 116 (26.5) 129 (23.2) 81 (18.7) 41 (15.0) 367
T4 39 (8.9) 51 (9.2) 56 (12.9) 48 (17.5) 194
Tx 27 (6.2) 45 (8.1) 25 (5.8) 18 (6.6) 115
Nodal status
Negative 174 (39.8) 238 (42.7) 191 (44.1) 122 (44.5) 725
Positive 263 (60.2) 319 (57.3) 242 (55.9) 152 (55.5) 976
* Figures in parenthesis shows the percentagesWorld Journal of Surgical Oncology 2004, 2 http://www.wjso.com/content/2/1/2
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senting with T3 and T4 lesion, the 10-year OS was 36.6%
and 10.4%. In the 40–49 age group, the 10-year OS was
41.9% and 33.5% for T3 and T4 lesions respectively
(Table 3). There was no significant difference in survival
by age among patients with T1, T2 and T3 tumors, how-
ever patients with T4 lesion showed significant difference
in survival between those <40 years and other age groups
(Table 4). The 10-year OS for women < 40 years with node
negativity was 76.8% in contrast to 24.2% for those with
node positivity (Table 5). Absence of axillary nodes
showed a significant difference in outcome among the
various age groups (p = 0.01) (Table 5). However, women
under 40 years with positive nodes had significantly
poorer survival in comparison with women aged 40–49,
and 50–59 years (p = 0.014 and p = 0.019 respectively)
(Table 6).
Overall Survival of women with breast carcinoma (N = 1701) Figure 1
Overall Survival of women with breast carcinoma (N = 1701)
Overall Survival of women with breast cancer by age group Figure 2
Overall Survival of women with breast cancer by age group
Overall Survival of women with T1 breast cancer by age  group Figure 3
Overall Survival of women with T1 breast cancer by age 
group
Overall Survival of women with T2 breast cancer by age  group Figure 4
Overall Survival of women with T2 breast cancer by age 
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The Cox-regression analysis showed that the prognosis
was significantly better among women with 40–49 years
(hazard ratio: 0.76; 95% CI: 0.62–0.93) compared to
patients under the age of 40 years after adjusting for both
T and N (Table 7). However, on adjusting for either T or
N all age groups showed uniform reduction in hazards
when compared with women <40 years of age (Table 7)
Discussion
In the present study of women with breast carcinomas we
have observed that the prognosis was worst in women
aged < 40 years and best in the 40–49 years of age group
after controlling for T and N.
Overall Survival of women with T3 breast cancer by age  group Figure 5
Overall Survival of women with T3 breast cancer by age 
group
Overall Survival of women with T4 breast cancer by age  group Figure 6
Overall Survival of women with T4 breast cancer by age 
group
Survival of women with node negative breast carcinoma by  age group Figure 7
Survival of women with node negative breast carcinoma by 
age group
Survival of women with node negative breast carcinoma by  age group Figure 8
Survival of women with node negative breast carcinoma by 
age groupWorld Journal of Surgical Oncology 2004, 2 http://www.wjso.com/content/2/1/2
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Table 2: Non-metastatic and non-inflammatory breast carcinoma: survival by different age groups (figures in parenthesis denotes 
%standard error).
Age (years) Overall Survival (%)
3-year 5-year 10-year
<40 69 (2) 58.5 (3) 46.5 (3)
40–49 75.1 (1) 65.5 (2) 59.8 (2)
50–59 75.6 (2) 67 (2) 58.9 (2)
60+ 71.9 (2) 61.6 (2) 48 (3)
p = 0.94
Table 3: Non-metastatic and non-inflammatory breast carcinoma: Overall survival (%) and standard error (%) of different age groups 
by tumor stage
Age 
(years)
T1 T2 T3 T4
3-yr 5-yr 10-yr 3-yr 5-yr 10-yr 3-yr 5-yr 10-yr 3-yr 5-yr 10-yr
<40 88.5 5 79.7 6 62.3 9 81.5 3 69.2 4 58.3 5 52.3 6 44.0 6 36.6 6 15.7 8 10.4 6 10.4 6
40–49 88.8 4 79.3 5 73.2 7 92.4 1 83.0 2 66.3 3 66.8 4 53.5 4 41.9 6 59.5 7 47.7 7 33.5 9
50–59 89.2 4 78.3 5 55.9 3 82.0 2 73.4 3 57.1 6 63.6 4 56.4 5 46.4 5 65.6 6 55.3 6 46.7 7
60+ 85.0 5 77.8 6 70.0 7 81.8 2 70.2 3 55.5 5 65.1 6 55.5 6 47.9 7 41.7 6 30.4 6 18.1 5
Overall p = 0.0046
Table 4: Non-metastatic and non-inflammatory breast carcinoma Log Rank Statistic and (p-value at 5% level)
For T = 1
Age group <40 40–49 50–59
40–49 0.75 (0.3866)
50–59 0.02 (0.8829) 0.63 (0.4264)
>60 0.01 (0.9300) 0.58 (0.4474) 0.01 (0.9305)
For T = 2
Age group < 40 40–49 50–59
40–49 0.98 (0.3223)
50–59 0.44 (0.5050) 0.11 (0.7432)
>60 0.04 (0.8439) 1.68 (0.1943) 0.94 (0.3335)
For T = 3
Age group < 40 40–49 50–59
40–49 1.89 (0.1690)
50–59 2.10 (0.1474) 0.03 (0.8619)
>60 2.00 (0.1569) 0.06 (0.8140) 0.01 (0.9084)
For T = 4
Age group < 40 40–49 50–59
40–49 15.48 (0.0001)
50–59 16.73 (0.0000) 0.42 (0.5174)
>60 5.94 (0.0148) 4.46 (0.0347) 7.58 (0.0059)World Journal of Surgical Oncology 2004, 2 http://www.wjso.com/content/2/1/2
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The influence of age on the prognosis of breast cancer still
remains controversial. Several studies based on registry
data showed poor prognosis for patients aged less than 35
or 40 years as compared to the older patients [2,4,6,10,18-
27]. In the present study, the survival was lower in women
under 40 years, with node positive disease and T3/T4
lesions. Holli et al. [28] found the poorest 10-year relative
survival rates for node-positive disease in women less
than 35 years of age. It is difficult to discern the biologic
reason as to why the occurrence of breast cancer in young
women is the worst. Some hereditary factors may suggest
the poor prognosis. It has been suggested that the poor
prognosis of younger women is due to underlying patho-
logical factors. Younger women have been shown to have
a higher likelihood of lymphatic invasion [23], extensive
ductal carcinoma in-situ in association with the invasive
component [29], estrogen receptor negativity [30] and
grade 3 histology [31]. However, despite controlling for
Table 5: Non-metastatic and non-inflammatory breast carcinoma: Overall Survival(%) of different age groups by nodal status (figures 
in parenthesis denotes standard error %).
Age (years) Node Negative Node Positive
3-year 5-year 10-year 3-year 5-year 10-year
<40 91.3 (2) 85.5 (3) 76.8 (4) 53.6 (4) 40.0 (4) 24.2 (5)
40–49 89.0 (2) 82.2 (2) 73.9 (3) 65.0 (2) 53.4 (3) 43.6 (3)
50–59 87.5 (2) 81.3 (2) 68.8 (6) 66.4 (3) 55.8 (3) 41.6 (4)
60+ 90.0 (2) 81.3 (3) 64.4 (6) 57.0 (3) 45.7 (3) 34.5 (4)
p = 0.01
Table 6: Non-metastatic and non-inflammatory breast carcinoma: Log Rank Statistic and the corresponding p-value (in parenthesis) 
adjusted for pathological node involvement.
Age groups <40 40–49 50–59
40–49 5.97 (0.0146)
50–59 5.46 (0.0195) 0.01 (0.9114)
>60 0.05 (0.8232) 5.49 (0.0191) 4.74 (0.0295)
Table 7: Non-metastatic and non-inflammatory breast carcinoma: Results of Cox-regression analysis
Age (years) Hazard ratio* 95% confidence interval
Adjusted for both T and N stage
<40 1.00 Referent
40–49 0.76 0.62–0.93*
50–59 1.00 0.83–1.27
>=60 0.95 0.74–1.21
Adjusted for T alone
<40 1.00 Referent
40–49 0.70 0.56–0.89*
50–59 0.71 0.56–0.90*
>=60 0.89 0.70–1.1
Adjusted for N stage alone
<40 1.00 Referent
40–49 0.75 0.60–0.94*
50–59 0.76 0.60–0.96*
>=60 0.97 0.76–1.2
*statistically significant at 5% levelWorld Journal of Surgical Oncology 2004, 2 http://www.wjso.com/content/2/1/2
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these factors the difference in survival remains the same
between various age groups as is seen in the present study.
In the present study we observed that women with age
>60 years and T4 disease had lower survival. This could be
due to less aggressive treatment received by this group of
women. Chemotherapy and radiotherapy are much more
commonly used to treat younger patients. Older patients
are often not keen to undergo more invasive therapies,
due to unique social fabric. More over, some of these may
have only a limited life span from coexisting disease or
may have cardiac contraindications to undergo intensive
cytotoxic therapy.
In the present study the best prognosis was observed in
the age group of 40–49 years after controlling for T and N.
Other studies have also demonstrated that women aged
40–49 years have the best prognosis [19,21]. The contrast
in survival observed in the present study between patients
aged 40–49 and younger than 40 years are remarkable.
The treatment procedures in these age groups are essen-
tially the same and their difference in outcome may be
related to the menstrual status, the former group being
peri-menopausal.
In conclusion, the general observation that young women
with breast cancer have a poorer outcome is established in
this study as well. Even though the suggested reasons for
this poor outcome are logical, more biological informa-
tion and integration of genetic treatment in addition to
chemotherapy and hormone therapy is the only answer to
improving their outcome.
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